---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-276891"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:51:51.509722+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Q3 2022 XPOVIO sales up 20% YoY; net loss narrows to $0.45/share; guidance reaffirmed

## Summary
- Total revenue $36.1M (-4% YoY); XPOVIO net product revenue $32.0M (+20% YoY).
- Net loss $36.3M ($0.45 per share) vs $51.8M ($0.69) in Q3 2021; cash $150.1M.
- Reaffirmed FY2022 guidance: total revenue $155-165M, XPOVIO $120-130M.
- Initiated Phase 3 selinexor maintenance in TP53 wild-type endometrial cancer; topline 2024.
- Phase 1 selinexor+ruxolitinib in myelofibrosis shows SVR35 at 79% at week 12; updated data at ASH.

## SEC filing metadata
- accession: 0001193125-22-276891
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/0001193125-22-276891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/d403188d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-276891
- JSON: https://secwatch.observer/filing/0001193125-22-276891.json
- Plain text: https://secwatch.observer/filing/0001193125-22-276891.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported the quarter ended September 30, 2022 results: revenue $36.1 Million. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2022
  - Revenue: $36.1 Million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved Third Quarter 2022 Total Revenue of $36.1 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/0001193125-22-276891-index.htm
- Earnings Releases
  Karyopharm Therapeutics Inc. reported full year 2022 results: revenue $155 Million to $165 Million. Guidance reaffirmed.
  - Period: full year 2022
  - Revenue: $155 Million to $165 Million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Company Re-Affirms Full Year 2022 XPOVIO Net Product Revenue Guidance of $120 Million to $130 Million, Total Revenue Guidance of $155 Million to $165 Million and Cash Runway into Early 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/0001193125-22-276891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.